Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1401 to 1450 of 3765 results for treatment

  1. Follow-up:- What is the optimal method, frequency and duration of follow-up for people who are disease-free after treatment for CUADT?

    frequency and duration of follow-up for people who are disease-free after treatment for CUADT? Any explanatory notes(if applicable) Why...

  2. Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) (TA859)

    After discussion with Paion AG, NICE is unable to make a recommendation on angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock. The company did not make an evidence submission because of uncertainty about the number of people who would be eligible for treatment. We will review this decision if the company decides to make a submission.

    Sections for TA859

  3. Peripheral arterial disease (QS52)

    This quality standard covers diagnosing and managing lower limb peripheral arterial disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  4. Erectile dysfunction: avanafil (ESNM45)

    Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making

  5. Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

    Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

  6. What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of psychological therapies in children aged 5 to 11 years with mild or moderate to severe depression?

    Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of psychological therapies in...

  7. Controlled drugs: safe use and management (NG46)

    This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.

  8. The MIST Therapy system for the promotion of wound healing (HTG267)

    Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.

  9. Danis stent for acute oesophageal variceal bleeding (HTG574)

    Evidence-based recommendations on Danis stent for acute oesophageal variceal bleeding.

  10. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.

  11. Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)

    Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making

  12. NICE supports the manufacturer's ongoing commitment to collect data on the effectiveness of enzalutamide after previous treatment with abiraterone.

    commitment to collect data on the effectiveness of enzalutamide after previous treatment with abiraterone. Any explanatory notes(if...

  13. NICE recommended that clinical data, including genotype and sustained virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS.

    virological response at 12 weeks, are collected for all people having treatment with simeprevir in the NHS. Any explanatory notes(if...

  14. Care setting: What is the clinical and cost effectiveness of different models of care for the prevention and treatment of early-onset neonatal infection?

    cost effectiveness of different models of care for the prevention and treatment of early-onset neonatal infection? Any explanatory...

  15. Safety, prognostic and predictive biomarkers: Can biomarkers be used for risk stratification and treatment planning for people with melanoma?

    predictive biomarkers: Can biomarkers be used for risk stratification and treatment planning for people with melanoma? Any explanatory...

  16. Children's attachment: attachment in children and young people who are adopted from care, in care or at high risk of going into care (NG26)

    This guideline covers the identification, assessment and treatment of attachment difficulties in children and young people up to age 18 who are adopted from care, in special guardianship, looked after by local authorities in foster homes (including kinship foster care), residential settings and other accommodation, or on the edge of care. It aims to address the many emotional and psychological needs of children and young people in these situations, including those resulting from maltreatment.

  17. The frequency and effects of biphasic reactions:- What are the frequency, timing, severity and predictors of biphasic reactions in people who have received emergency treatment for anaphylaxis?

    predictors of biphasic reactions in people who have received emergency treatment for anaphylaxis? Any explanatory notes(if applicable)...

  18. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.

  19. What is the effectiveness and safety of sacral nerve stimulation and transanal irrigation compared to symptomatic treatment for people with major low anterior resection syndrome?

    sacral nerve stimulation and transanal irrigation compared to symptomatic treatment for people with major low anterior resection...

  20. Idiopathic sudden sensorineural hearing loss:- What is the most effective route of administration of steroids as a first-line treatment for idiopathic sudden sensorineural hearing loss?

    the most effective route of administration of steroids as a first-line treatment for idiopathic sudden sensorineural hearing loss? Any...

  21. 3C Patch for treating diabetic foot ulcers (HTG615)

    Evidence-based recommendations on 3C Patch for treating diabetic foot ulcers.

  22. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.

  23. Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) (TA1112)

    NICE is unable to make a recommendation on trastuzumab deruxtecan (Enhertu) for treating hormone receptor-positive HER2-low metastatic breast cancer in adults after 2 or more endocrine treatments. This is because the company did not provide an evidence submission.

    Sections for TA1112

  24. What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?

    is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes? Any explanatory notes(if...

  25. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

  26. Tobacco: preventing uptake, promoting quitting and treating dependence (NG209)

    This guideline covers support to stop smoking for everyone aged 12 and over, and help to reduce people's harm from smoking if they are not ready to stop in one go. It also covers ways to prevent children, young people and young adults aged 24 and under from taking up smoking.

  27. Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment (HTG748)

    Early value assessment (EVA) guidance on digital therapy for chronic tic disorders and Tourette syndrome.

  28. Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers (HTG677)

    Evidence-based recommendations on automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers.

  29. Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

    Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

  30. Postural hypotension in adults: fludrocortisone (ESUOM20)

    Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

  31. EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (HTG296)

    Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.

  32. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)

    Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

  33. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

  34. For which service users who are moderately and severely dependent on alcohol is an assertive community treatment model a clinically and cost-effective intervention compared with standard care?

    moderately and severely dependent on alcohol is an assertive community treatment model a clinically and cost-effective intervention...

  35. Intrapartum care for women with existing medical conditions or obstetric complications and their babies (NG121)

    This guideline covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. The guideline also covers women who have had no antenatal care. It aims to improve experiences and outcomes for women and their babies.

  36. Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)

    Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults

  37. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    In development Reference number: GID-TA11468 Expected publication date:  14 May 2026

  38. Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments ID6363

    In development Reference number: GID-TA11422 Expected publication date: TBC

  39. Epilepsy: annual review (IND227)

    This indicator covers the percentage of adults receiving drug treatment for epilepsy who had a structured review in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM209

  40. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)

    Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

  41. What is the cost effectiveness and safety of non-surgical ablation and stereotactic body radiotherapy compared to resection for people with metastatic colorectal cancer in the lung amenable to local treatment?

    people with metastatic colorectal cancer in the lung amenable to local treatment? Any explanatory notes(if applicable) Why the committee...

  42. Chronic anal fissure: botulinum toxin type A injection (ESUOM14)

    Summary of the evidence on botulinum toxin type A injection for treating chronic anal fissure to inform local NHS planning and decision-making

  43. CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment (HTG663)

    Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.

  44. Skin involvement in systemic sclerosis: rituximab (ES7)

    Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

  45. NICE considered that there is an important need for head-to-head comparisons between biological treatments for psoriatic arthritis, particularly in people for whom treatment with tumour necrosis factor (TNF) alpha inhibitors has been unsuccessful.

    head-to-head comparisons between biological treatments for psoriatic arthritis, particularly in people for whom treatment...